CD274 and hepatocellular carcinoma: Currently, several prospective clinical studies (NCT04961918, NCT05029973, NCT04947826, and NCT05003700) are underway to assess the efficacy of HAIC in conjunction with anti-PD-1/PD-L1 immunotherapy and molecular targeted therapy for advanced HCC, as well as the effectiveness of conversion therapy.